...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith new VP
3
Jul 28, 2017 11:55PM
2
Jul 29, 2017 12:03AM
1
Jul 29, 2017 12:17AM
3
Jul 29, 2017 06:48PM
1
Jul 29, 2017 07:12PM
3
Jul 30, 2017 08:49AM
3
Jul 30, 2017 12:44PM
2
Jul 31, 2017 12:31AM

Jul 31, 2017 01:09AM
2
Jul 31, 2017 09:07AM

Jul 31, 2017 11:09AM

Jul 31, 2017 09:15PM

Aug 01, 2017 10:03AM
1
Aug 01, 2017 10:59AM

Aug 01, 2017 11:04AM
1
Aug 01, 2017 12:57PM
2
Aug 01, 2017 01:37PM

Aug 01, 2017 06:16PM
1
Aug 02, 2017 01:05AM

Aug 02, 2017 09:56AM

It appears that the new VP hire is a done deal. Edward van der Horst's LinkedIn profile lists the following:

"Vice President Discovery Biology & Preclinical Development

Zenith Epigenetics Corp.

Jul 2017 – Present

San Francisco Bay Area"

3
Aug 03, 2017 12:33PM
4
Aug 03, 2017 12:57PM
2
Dec 07, 2017 03:04PM
Share
New Message
Please login to post a reply